Abstract:Identification of immunogenic targets against hepatitis B virus (HBV)-encoded proteins will provide crucial advances in developing potential antibody therapies. In this study, 63 treatment-naive patients with chronic HBV infection and 46 patients who achieved hepatitis B surface antigen loss (sAg loss) following antiviral treatment were recruited. Moreover, six patients who transitioned from the hepatitis B e antigen-positive chronic infection phase (eAg(+)CInf) to the hepatitis phase (eAg(+)CHep) were enrolled from real-life clinical practice. Additionally, telbivudine-treated eAg(+)CHep patients and relapsers or responders from an off-treatment cohort were longitudinally studied. The frequencies and function of B cells were assessed by flow cytometry. We devised a peptide array composed of 15-mer overlapping peptides of HBV-encoded surface (S), core (C), and polymerase (P) proteins and performed a screening on B-cell linear epitopes with sera. Naive B cells and plasmablasts were increased, whereas total memory, activated memory (AM), and atypical memory (AtM) B cells were reduced in sAg(-) patients compared with sAg(+) patients. Importantly, longitudinal observations found that AtM B cells were associated with successful treatment withdrawal. Interestingly, we identified six S-specific dominant epitopes (S33, S34, S45, S76, S78, and S89) and one C-specific dominant epitope (C37) that reacted with the majority of sera from sAg(-) patients. Of note, more B-cell linear epitopes were detected in CHep patients with alanine aminotransferase (ALT) flares than in nonflare CInf patients, and five B-cell linear epitopes (S4, S5, S10, S11, and S68) were overwhelmingly recognized by ALT flare patients. The recognition rates of epitopes on C and P proteins were significantly increased in CHep patients relative to CInf patients. Strikingly, a statistically significant elevation in the number of positive epitopes was observed when ALT nonflare patients shifted into the flare phase. Moreover, S76 identified at baseline was confirmed to be associated with a complete response after 48 weeks of telbivudine therapy. Taken together, we identified several functional cure-related B-cell linear epitopes of chronic HBV infection, and these epitopes may serve as vaccine candidates to elicit neutralizing antibodies to treat HBV infection.

Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance

Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Non-neutralizing Epitopes Induce Robust Hepatitis C Virus (Hcv)-Specific Antibody-Dependent CD56+natural Killer Cell Responses in Chronic HCV-infected Patients

Characterization of antibody‐dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes

Determination of the Human Antibody Response to the Neutralization Epitopes Encompassing Amino Acids 313-327 and 432-443 of Hepatitis C Virus E1e2 Glycoproteins

HCV neutralization goes elite

Discovery of a monoclonal, high‐affinity CD8+ T‐cell clone following natural hepatitis C virus infection

Signatures of VH1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins

Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.

A Laboratory-Adapted Hcv Jfh-1 Strain Is Sensitive To Neutralization And Can Gradually Escape Under The Selection Pressure Of Neutralizing Human Plasma

Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

Hepatitis C virus hypervariable region 1 antibodies interrupt E2-SR-B1 interaction to suppress viral infection

Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus

Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants

Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization